Zivo Bioscience Inc. Secures $2 Million Convertible Debt Financing to Accelerate Growth

Reuters07-15

<a href="https://laohu8.com/S/ZIVO">Zivo Bioscience</a> Inc. Secures $2 Million Convertible Debt Financing to Accelerate Growth

Zivo Bioscience Inc. has announced a new convertible debt financing agreement dated July 8, 2025, as part of its efforts to raise $2 million. The company has issued a Bridge Promissory Note valued at $250,000 along with a warrant to purchase 1,793 shares of its common stock to an accredited investor. The notes, accruing 10% annual interest, will mature either two years post-issuance or following a qualified equity financing of $5 million. Upon maturity or qualified financing, outstanding principal and interest will convert into common stock at a discounted rate. The unsecured notes rank junior to secured debts and include provisions for early repayment with investor consent. Additionally, accompanying warrants have a five-year term and are immediately exercisable. This financing move highlights Zivo Bioscience's strategic efforts to bolster its financial position.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zivo Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001654954-25-008035), on July 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2551335136?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-15 04:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551335136","market":"us","top_or_hot":-1,"title":"Zivo Bioscience Inc. Secures $2 Million Convertible Debt Financing to Accelerate Growth","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ZIVO\">Zivo Bioscience</a> Inc. Secures $2 Million Convertible Debt Financing to Accelerate Growth\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ZIVOW\">Zivo Bioscience</a> Inc. has announced a new convertible debt financing agreement dated July 8, 2025, as part of its efforts to raise $2 million. The company has issued a Bridge Promissory Note valued at $250,000 along with a warrant to purchase 1,793 shares of its common stock to an accredited investor. The notes, accruing 10% annual interest, will mature either two years post-issuance or following a qualified equity financing of $5 million. Upon maturity or qualified financing, outstanding principal and interest will convert into common stock at a discounted rate. The unsecured notes rank junior to secured debts and include provisions for early repayment with investor consent. Additionally, accompanying warrants have a five-year term and are immediately exercisable. This financing move highlights Zivo Bioscience's strategic efforts to bolster its financial position.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zivo Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001654954-25-008035), on July 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zivo Bioscience Inc. Secures $2 Million Convertible Debt Financing to Accelerate Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZivo Bioscience Inc. Secures $2 Million Convertible Debt Financing to Accelerate Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-15 04:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ZIVO\">Zivo Bioscience</a> Inc. Secures $2 Million Convertible Debt Financing to Accelerate Growth\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ZIVOW\">Zivo Bioscience</a> Inc. has announced a new convertible debt financing agreement dated July 8, 2025, as part of its efforts to raise $2 million. The company has issued a Bridge Promissory Note valued at $250,000 along with a warrant to purchase 1,793 shares of its common stock to an accredited investor. The notes, accruing 10% annual interest, will mature either two years post-issuance or following a qualified equity financing of $5 million. Upon maturity or qualified financing, outstanding principal and interest will convert into common stock at a discounted rate. The unsecured notes rank junior to secured debts and include provisions for early repayment with investor consent. Additionally, accompanying warrants have a five-year term and are immediately exercisable. This financing move highlights Zivo Bioscience's strategic efforts to bolster its financial position.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zivo Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001654954-25-008035), on July 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4183","symbol_name":"个人用品","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nNDL3kVy45:1","article_id":"2551335136","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551335136","pubTimestamp":1752526796,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zivo Bioscience Inc. has announced a new convertible debt financing agreement dated July 8, 2025, as part of its efforts to raise $2 million. The company has issued a Bridge Promissory Note valued at $250,000 along with a warrant to purchase 1,793 shares of its common stock to an accredited investor. The notes, accruing 10% annual interest, will mature either two years post-issuance or following a qualified equity financing of $5 million. Upon maturity or qualified financing, outstanding principal and interest will convert into common stock at a discounted rate. The unsecured notes rank junior to secured debts and include provisions for early repayment with investor consent. Additionally, accompanying warrants have a five-year term and are immediately exercisable. This financing move highlights Zivo Bioscience's strategic efforts to bolster its financial position.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4183":"个人用品","ZIVO":"Zivo Bioscience, Inc."},"translate_title":"Zivo Bioscience Inc.获得200万美元可转换债务融资以加速增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZIVO":0.9},"content_text":"Zivo Bioscience Inc. Secures $2 Million Convertible Debt Financing to Accelerate Growth\n    \n\nZivo Bioscience Inc. has announced a new convertible debt financing agreement dated July 8, 2025, as part of its efforts to raise $2 million. The company has issued a Bridge Promissory Note valued at $250,000 along with a warrant to purchase 1,793 shares of its common stock to an accredited investor. The notes, accruing 10% annual interest, will mature either two years post-issuance or following a qualified equity financing of $5 million. Upon maturity or qualified financing, outstanding principal and interest will convert into common stock at a discounted rate. The unsecured notes rank junior to secured debts and include provisions for early repayment with investor consent. Additionally, accompanying warrants have a five-year term and are immediately exercisable. This financing move highlights Zivo Bioscience's strategic efforts to bolster its financial position.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zivo Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001654954-25-008035), on July 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2551335136","isCrawlerRequest":true}